CBIO
Crescent Biopharma, Inc.
14.30$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.8% | -24.5% | -28.6% | -35.7% | -29.3% | -46.0% | +2,527.3% | -12.2% | +73.8% | -17.1% | -8.2% | |
| – | -15.8% | -24.0% | -28.3% | -34.4% | -29.1% | -46.0% | +2,473.8% | -12.8% | +75.9% | -17.4% | -8.5% | |
| – | -15.4% | -25.2% | -28.4% | -35.7% | -25.5% | -47.6% | +2,618.9% | -12.7% | +60.0% | -11.3% | -9.3% | |
| – | -15.4% | -25.2% | -28.4% | -35.7% | -25.5% | -47.6% | +2,618.9% | -12.7% | +60.0% | -11.3% | -9.3% | |
| – | -6.9% | -37.5% | -30.2% | -34.5% | +171.8% | – | – | – | – | -100.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.7% | -23.3% | -17.7% | -0.8% | +33.7% | -54.7% | +594.7% | +19.0% | +72.4% | -59.0% | +27.6% | |
| – | +7.0% | -22.5% | -17.7% | -0.8% | +33.7% | -54.7% | +539.9% | +21.2% | +77.7% | -60.7% | +30.6% | |
| – | -1.1% | -14.9% | -28.9% | -41.6% | -74.5% | – | – | +97.6% | +4.3% | +4.1% | +4.0% | |
| – | +163.2% | -13.0% | +25.8% | +6.2% | +36.5% | -89.2% | +1,011.6% | +55.4% | +290.4% | -88.1% | +113.6% | |
| – | -17.5% | -24.7% | -30.6% | -43.3% | -53.3% | -36.5% | +4,025.7% | -16.2% | +74.0% | -9.4% | -11.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.1% | +0.0% | +0.0% | +0.0% | +19.7% | +399.7% | +328.9% | +21.9% | +50.7% | +0.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.